Connor, Clark & Lunn Investment Management Ltd. Myriad Genetics Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,387,832 shares of MYGN stock, worth $11 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,387,832
Previous 921,911
50.54%
Holding current value
$11 Million
Previous $8.18 Million
9.88%
% of portfolio
0.03%
Previous 0.04%
Shares
18 transactions
Others Institutions Holding MYGN
# of Institutions
235Shares Held
95.3MCall Options Held
460KPut Options Held
14.2K-
Black Rock Inc. New York, NY15.2MShares$120 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.26MShares$73.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.92MShares$38.9 Million0.01% of portfolio
-
State Street Corp Boston, MA4.81MShares$38 Million0.0% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$36.2 Million0.69% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $637M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...